Relay Therapeutics CFO Sells Shares Worth $350K via Pre-Arranged Trading Plan
Thomas Catinazzo, Chief Financial Officer of Relay Therapeutics (NASDAQ: RLAY), sold 17,717 shares on August 14, 2026, for a total value of approximately $350,000. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan established in October 2025, which is designed to provide structured liquidity and avoid insider trading concerns. Following the sale, Catinazzo retained ownership of 140,568 shares with an estimated market value of $2.9 million as of August 17, 2026. Relay Therapeutics has a current market capitalization of approximately $4 billion and reported a trailing twelve-month net loss of $286 million on revenue of just $10.3 million. The company is focused on developing small-molecule therapies for oncology-related pathways with its lead candidate, RLY-4008, in clinical trials.
